Three methods for 18F labeling of the HER2-binding affibody molecule ZHER2:2891 including preclinical assessment

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 1981-1988

  Glaser, Matthias ^a   Iveson, Peter ^a   Hoppmann, Susan ^a   Indrevoll, Bard ^a   Wilson, Anthony ^a   Arukwe, Joseph ^b   Danikas, Antonios ^a   Bhalla, Rajiv ^a   Hiscock, Duncan ^a  

^a GE HEALTHCARE   (United Kingdom)

^b GE HEALTHCARE   (Norway)

Author keywords

Affibody molecule; AlF NOTA; FBA; HER2 receptor; SiFA

Indexed keywords

CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORIDE; FLUORINE 18; MALEIMIDE; SILICON; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; BENZALDEHYDE; BENZALDEHYDE DERIVATIVE; DIAGNOSTIC AGENT; ERBB2 PROTEIN, HUMAN; FLUORINE; HETEROCYCLIC COMPOUND; HYBRID PROTEIN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; CONJUGATION; DEFLUORINATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOACTIVITY; RADIOCHEMISTRY; TUMOR LOCALIZATION; TUMOR XENOGRAFT; AFFIBODY MOLECULE; ALF-NOTA; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; FBA; HER2-RECEPTOR; HUMAN; METABOLISM; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; SIFA; TUMOR CELL LINE; DIAGNOSTIC USE; PROCEDURES;

18F; AFFIBODY MOLECULE; ALF-NOTA; FBA; HER2-RECEPTOR; SIFA;

ANIMALS; BENZALDEHYDES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FLUORINE RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HUMANS; ISOTOPE LABELING; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOCHEMISTRY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SILICON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84891666608     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.122465     Document Type: Article

References (34)

1. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15:7479-7491.
2. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990; 45:457-461.
3. Gradishar WJ. HER2 therapy: an abundance of riches. N Engl J Med. 2012;366: 176-178.
4. Orlova A, Magnusson M, Eriksson TLJ, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339-4348.
5. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-2680.
6. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for Affibody molecules. J Mol Biol. 2010;398:232-247.
7. 111In-ABY-025, a second-generation Affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010;51:1131-1138.
8. Sandberg D, Wennborg A, Feldwisch J, et al. First-in-human whole-body HER2-receptor mapping using affibody molecular imaging. Cancer Res. 2011;71(24 suppl): P2-09-01.
9. 111In-labelled analogue. Eur J Nucl Med Mol Imaging. 2010;37:1356-1367.
10. 111In-or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-897.
11. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858-2902.
12. Kramer-Marek G, Gijsen M, Kiesewetter DO, et al. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med. 2012;53:629-637.
13. 18F-FDG. J Nucl Med. 2012;53:939-946.
14. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18Flabeled Affibody molecules. J Nucl Med. 2009;50:1131-1139.
15. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [F-18]FBEM-Z(HER2: 342): Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35:1008-1018.
16. Kiesewetter DO, Krämer-Marek G, Ma Y, Capala J. Radiolabelling of HER2-specific Affibody® molecule with F-18. J Fluor Chem. 2008;129:799-805.
17. 18F-labeled affibody molecule. J Nucl Med. 2012;53:1110-1118.
18. 18F]GBR-13119. J Labelled Comp Radiopharm. 1989;27:823-833.
19. 18F-labeled protein scaffold molecules. J Nucl Med. 2008;49:804-813.
20. Dirksen A, Dawson PE. Rapid oxime and hydrazone ligations with aromatic aldehydes for biomolecular labeling. Bioconjug Chem. 2008;19:2543-2548.
21. Flavell RR, Kothari P, Bar-Dagan M, et al. Site-specific F-18-labeling of the protein hormone leptin using a general two-step ligation procedure. J Am Chem Soc. 2008;130:9106-9112.
22. 18F]exendin (9-39) as a potential biomarker to measure pancreatic b-cell mass. Nucl Med Biol. 2012;39:167-176.
23. 18F-labelled peptides. Eur J Inorg Chem. 2011;2238-2246.
24. 18F-labeling of N-amino-oxy derivatized peptides. Bioconjug Chem. 2007;18:2085-2089.
25. McBride WJ, D'Souza CA, Karacay H, Sharkey RM, Goldenberg DM. New lyophilized kit for rapid radiofluorination of peptides. Bioconjug Chem. 2012;23:538-547.
26. 18F-labeled bombesin analog. J Nucl Med. 2012;53:947-952.
27. McBride WJ, D'Souza CA, Sharkey RM, et al. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010;21:1331-1340.
28. Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide. J Nucl Med. 2010;51:454-461.
29. McBride WJ, Sharkey RM, Karacay H, et al. A novel method of F-18 radiolabeling for PET. J Nucl Med. 2009;50:991-998.
30. 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med. 2012;53:146-153.
31. 18F]fluciclatide of the FASTlab synthesiser using chemometric design. Q J Nucl Med. 2010;54:26-27.
32. 18F-labeled aVb3-integrin and aVb5-integrin imaging agent. J Nucl Med. 2011;52:424-430.
33. 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.
34. Tolmachev V, Wallberg H, Sandström M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging. 2011;38:531-539.